How AST, ALT, platelets, A1C, lipids, and secondary fibrosis tests work together to guide evaluation and follow-up.
MASLD fibrosis risk can be present even when liver enzymes fall within the laboratory reference interval. Metabolic dysfunction-associated steatotic liver disease (MASLD) means liver fat occurs with cardiometabolic risk. Fibrosis is scar tissue. The important next question is whether scarring is likely enough to require a more specific assessment.
A staged evaluation combines medical history and routine laboratory results, calculates FIB-4 when appropriate, and uses elastography or an Enhanced Liver Fibrosis (ELF) Score when further assessment is needed. Ulta Lab Tests provides access to many supporting blood tests. Results require interpretation by a qualified healthcare professional and do not replace imaging, diagnosis, or individualized care.
MASLD describes hepatic steatosis—excess liver fat—plus at least one defined cardiometabolic risk factor. MASH, formerly called NASH, adds liver-cell injury and inflammation. Fibrosis may occur with MASH, but inflammation and scarring are different findings. Histologic stages range from F0, no fibrosis, through F4, cirrhosis; clinically significant fibrosis generally means F2 or greater, while advanced fibrosis usually means F3–F4.
MetALD describes overlapping metabolic dysfunction and alcohol exposure within specified ranges. Alcohol and metabolic risk can contribute together. The classification thresholds are not personal safe-drinking limits. For terminology and first evaluation, read the introductory MASLD blood-testing guide and the AASLD nomenclature framework.
Symptoms and enzyme levels do not reliably reveal the amount of scar tissue. A person can feel well while fibrosis develops. Conversely, fatigue or abdominal discomfort can have many explanations and cannot establish liver disease.
ALT (alanine aminotransferase) and AST (aspartate aminotransferase) mainly provide information about cell injury. They do not directly measure liver fat, inflammation under a microscope, or scar tissue. Fibrosis assessment matters because stage helps predict liver-related complications and informs follow-up. Cardiovascular, diabetes, and kidney risks also need attention. These distinctions underpin the AASLD assessment guidance.
| Finding | Why it matters | Useful next information |
|---|---|---|
| Type 2 diabetes; prediabetes with additional metabolic risks | Higher-risk setting for metabolic liver disease | Current liver chemistry, CBC with platelets, A1C, and an appropriate FIB-4 calculation |
| Obesity or abdominal adiposity with metabolic complications | Risk increases as cardiometabolic factors cluster | Blood pressure, glucose, lipid panel, history, and selected fibrosis assessment |
| Liver fat reported on imaging | Steatosis does not establish fibrosis stage | Clinical review and fibrosis risk stratification |
| Persistent ALT or AST elevation | Ongoing injury may have a competing cause | Exposure review and targeted blood tests or imaging |
| Falling platelets or family history of MASLD-related cirrhosis | May increase concern but is not diagnostic | Repeat comparable results and timely clinical assessment |
These are risk-based discussions, not a recommendation for population-wide testing or a broad panel for every reader. People with suspected cirrhosis, significant symptoms, or rapidly changing results may need direct specialist assessment.
A Comprehensive Metabolic Panel (CMP) and CBC with Differential and Platelets commonly supply liver chemistry and the platelet input. CBC means complete blood count. Hemoglobin A1C reflects longer-term glucose exposure, while a lipid panel describes cholesterol and triglyceride-related risk. Use clinically comparable AST, ALT, and platelet results, preferably from the same collection. Review recent illness, strenuous exercise, alcohol, supplements, and prescribed medicines before calculating.
FIB-4 = (age × AST) ÷ (platelets × √ALT). Age is in years, enzymes in U/L, and platelets in ×109/L. The FIB-4 calculation guide explains units and worked examples.
| Age | Lower probability | Secondary assessment | Higher concern |
|---|---|---|---|
| 35–64 years | Below 1.3 | 1.3–2.67 | Above 2.67 |
| 65 years or older | Below 2.0 | 2.0–2.67 | Above 2.67 |
| Younger than 35 | Accuracy is limited. Substantial metabolic risk or persistent liver abnormalities may justify another assessment despite a low score. | ||
The age bands above follow the 2026 AGA pathway summary; AASLD's earlier guidance describes the older group as over 65. Use the clinician's selected pathway at that boundary. Do not use FIB-4 to assess chronic fibrosis during acute illness. A low result reduces the probability of advanced fibrosis; it does not exclude all fibrosis, MASH, or another liver disorder.
Secondary tests refine risk; they do not simply repeat the information in liver enzymes. Vibration-controlled transient elastography (VCTE), often called FibroScan, estimates liver stiffness. ELF is a blood-based score related to extracellular-matrix turnover. Magnetic resonance elastography may help with selected or discordant findings.
| Assessment | Practical interpretation | Limitations |
|---|---|---|
| VCTE/FibroScan | Below 8 kPa generally supports lower risk; 8 kPa or higher prompts further stratification or referral in the AGA pathway. | Food intake, inflammation, congestion, body habitus, and measurement quality affect stiffness. A value of 8 kPa is not a diagnosis of advanced fibrosis. |
| Enhanced Liver Fibrosis (ELF) Score | Provides additional fibrosis-risk information when appropriate, including when elastography is unavailable. | A score must be interpreted using the intended pathway and population. |
| Magnetic resonance elastography | May clarify risk when initial tests disagree or concern remains. | Access, cost, and technical factors affect suitability. |
| Liver biopsy | Examines fat, inflammation, cell injury, and fibrosis in tissue. | Invasive and subject to sampling variation; not required for every patient. |
FibroScan, magnetic resonance elastography, and biopsy are procedures arranged through clinical services. Routine ultrasound may identify steatosis but cannot reliably stage fibrosis or prove MASH. The NIDDK diagnosis guide explains these distinctions.
The 2026 AGA pathway summary uses an ELF threshold of 9.2 for identifying clinically significant fibrosis when elastography is unavailable. The AASLD guidance lists 9.8 in its advanced-fibrosis assessment table and discusses 11.3 for predicting liver-related events in people with suspected or confirmed advanced disease. Different endpoints and clinical settings explain why these values are not interchangeable. An ELF result between 9.2 and 9.8 should not automatically be dismissed as reassuring.
Metabolic risk does not exclude viral hepatitis, iron overload, autoimmune disease, medication injury, or alcohol-related disease. A clinician may select a hepatitis B triple panel (HBsAg, anti-HBs, and total anti-HBc), Hepatitis C Antibody with Reflex to HCV RNA, or ferritin with iron and TIBC (total iron-binding capacity). Persistent unexplained findings may justify ANA (antinuclear antibodies), smooth-muscle antibody, and IgG (immunoglobulin G). Positive autoimmune markers alone do not establish autoimmune hepatitis. CK (creatine kinase) may clarify an AST elevation associated with muscle injury.
| Test or panel | Role and possible findings | Important limitation |
|---|---|---|
| FIB-4 Index Liver Health Evaluation (Self Calculation) | Laboratory inputs used with age to estimate advanced-fibrosis probability | A calculation, not a tissue measurement or cirrhosis diagnosis |
| Comprehensive Metabolic Panel (CMP) | Liver chemistry, glucose, and kidney context; abnormal patterns guide evaluation | Does not measure liver fat or scarring directly |
| CBC with Differential and Platelets | Platelets for the calculation; blood-cell findings may reveal other problems | Low platelets have many non-liver causes |
| Hemoglobin A1C and lipid panel | Glucose exposure and lipid-related cardiovascular risk | Improvement does not prove fibrosis regression |
| Apolipoprotein B | Selected cardiovascular assessment when particle-related risk needs clarification | Not a fibrosis marker or universal requirement |
| Ferritin, Iron and TIBC Panel | Iron storage and availability; saturation helps investigate overload | Ferritin also rises with inflammation and liver injury |
| Enhanced Liver Fibrosis (ELF) Score | Secondary fibrosis-risk assessment | Threshold and intended use matter |
| Albumin Random Urine with Creatinine | Kidney-injury assessment when diabetes or another indication warrants it | Urine findings can be transient and do not stage liver disease |
The following examples are fictional teaching cases, not diagnostic rules. Enzymes are in U/L, platelets in ×109/L, ferritin in ng/mL, and transferrin saturation in percent. Laboratory reference intervals vary.
| Pattern | What it illustrates | Discussion to have |
|---|---|---|
| Age 60; AST 30; ALT 25; platelets 120; FIB-4 3.00 | Enzymes may be within the reported interval while fibrosis risk is elevated. | Arrange secondary assessment and investigate the low platelet count. |
| Age 50; AST 60; ALT 90; platelets 350; FIB-4 0.90; enzymes persistently elevated for over six months | A low fibrosis-risk score does not explain persistent injury. | Evaluate alternative or coexisting causes. |
| Ferritin 450; transferrin saturation 24% | Ferritin alone cannot establish iron overload. | Consider inflammation, liver injury, alcohol, and other explanations. |
| Ferritin 450; transferrin saturation 68% | Persistently high saturation increases concern about iron loading. | Discuss focused iron-overload evaluation; do not self-diagnose. |
| A1C, weight, and ALT improve, but an appropriately interpreted fibrosis assessment remains concerning | Metabolic improvement and residual liver risk can coexist. | Complete the planned fibrosis follow-up. |
Follow the metabolic pattern and the fibrosis question separately, then interpret them together. A1C describes glucose exposure; lipid results describe cardiovascular risk; enzymes describe injury signals; and fibrosis assessments address scarring probability. None is a substitute for the others.
FIB-4 changes can reflect aging, enzyme fluctuations, or a platelet change unrelated to the liver. Improvement in the score may be encouraging but does not, by itself, prove scar tissue has regressed. Likewise, rising scores do not automatically prove progression. Comparable collection conditions and secondary testing help resolve uncertainty. See the whole-body liver laboratory dashboard for the broader connections.
AASLD commonly recommends repeating FIB-4 every one to two years for people with prediabetes, type 2 diabetes, or multiple metabolic risks, and every two to three years for selected people without prediabetes or diabetes and with fewer risks. The AGA pathway uses one- to two-year reassessment for low-risk patients. A clinician chooses the interval. An indeterminate or higher-risk result generally requires secondary evaluation rather than waiting for the next routine check.
Smaller sustained weight reductions may improve liver fat; AASLD describes about 3%–5% for steatosis improvement and generally greater than 10% for improvement in steatohepatitis and fibrosis. These are population findings, not individual guarantees. Physical activity and management of glucose, blood pressure, and cardiovascular risk remain relevant.
FDA has approved resmetirom and Wegovy (semaglutide) injection for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis, under accelerated approval. A high enzyme value or FIB-4 alone does not establish eligibility. Disease staging, current labeling, interactions, and contraindications require clinician review. See the FDA announcements for resmetirom and Wegovy for MASH. Do not start, stop, or change medication based on this article.
Check the instructions for the exact ordered tests. The FIB-4 calculation itself does not require fasting, but accompanying glucose or lipid testing may have specific instructions. Bring identification and collection paperwork as directed. Report recent illness, exercise, alcohol, and medicines; do not stop a prescription without instructions from the prescriber.
Vomiting blood, black tarry stools with weakness or fainting, or new confusion or marked drowsiness can be emergencies: seek emergency care immediately. New jaundice, rapidly increasing abdominal swelling, or severe upper-abdominal pain with fever or vomiting requires urgent assessment. Do not delay care to order routine blood tests.
Ulta Lab Tests lets patients explore many laboratory tests online where available, review listed prices, and receive results through a secure portal. Testing uses established laboratory services, including Quest Diagnostics where applicable. Insurance is not required, and eligible HSA/FSA payment may be available. Choose tests around a defined clinical question and review results with a qualified healthcare professional.
No. ALT can be within the laboratory reference interval despite clinically important scarring. Interpretation also considers metabolic risk, imaging, platelets, and an appropriate fibrosis assessment. A normal enzyme result is information about that measurement, not proof that liver fat, MASH, or fibrosis is absent.
Many pathways begin with FIB-4, a calculation using age, AST, ALT, and platelets. The laboratory inputs may already be available from suitable recent testing. It estimates advanced-fibrosis probability and helps decide whether another assessment is appropriate; it is not a stand-alone diagnosis or a direct measurement of scarring.
No. A high score raises concern but can also reflect age, muscle-related AST elevation, acute illness, or low platelets from another condition. A healthcare professional reviews the inputs and may arrange elastography, ELF, or specialist evaluation. Do not translate the numerical score directly into a fibrosis stage.
No. ELF is a blood-based composite score related to fibrosis-associated matrix turnover. FibroScan is an imaging-based procedure that estimates liver stiffness and can also assess steatosis through a separate measurement. They supply different information and have different limitations; the best next assessment depends on clinical context and availability.
Thresholds depend on the pathway, population, and clinical endpoint. The AGA summary uses 9.2 for clinically significant fibrosis detection, whereas AASLD lists 9.8 for advanced-fibrosis assessment. Neither number should be treated as a universal diagnostic boundary. Ask which framework applies to the result and what follow-up it supports.
Lower A1C can indicate improved glucose exposure, which is valuable for metabolic health. It does not measure liver scarring. Enzymes, platelets, clinical findings, and fibrosis assessments may follow different timelines. Continue the agreed follow-up plan even when glucose control, weight, or other metabolic results improve substantially.
Not everyone does. Clinicians often use noninvasive assessments first. Biopsy may help when results conflict, another diagnosis remains possible, or greater certainty would change care. The decision weighs likely benefit against procedural risks and sampling limitations; a high FIB-4 alone does not automatically require biopsy.
Many supporting tests can be ordered online through Ulta Lab Tests where available. Ordering access does not replace clinical interpretation or arrange imaging automatically. Review appropriate tests with a healthcare professional, especially when a score is elevated, symptoms are present, or you already have known liver disease.
Useful testing connects the reason for concern with the next decision. Explore the linked blood tests, discuss whether your existing results are sufficient, and make a plan for secondary assessment when needed. For broader liver-test interpretation, use the Liver Function Tests guide.
Originally published: August 6, 2026 | Updated: September 17, 2026
These tests should be selected according to the history and laboratory pattern rather than ordered routinely for everyone.
Liver Tests, Diabetes Tests, Weight Management Tests, Kidney Tests.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
